International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled "Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process." The guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The purpose of the guidance is to provide principles for assessing the comparability of biotechnological/biological products before and after changes are made in the manufacturing process for the drug substance or drug product. The guidance is intended to assist in the collection of relevant technical information that serves as evidence that the manufacturing process changes will not have an adverse impact on the quality, safety, and efficacy of the drug product.
D001688:Biological Products / Q000592:standards*; D002626:Chemistry, Pharmaceutical / Q000592:standards*; D003226:Congresses as Topic; D004339:Drug Compounding / Q000592:standards*; D004341:Drug Evaluation; D005060:Europe; D005062:European Union; D006801:Humans; D007391:International Cooperation; D007564:Japan; D011786:Quality Control; D014481:United States; D014486:United States Food and Drug Administration
D001688:Biological Products